Synaptic degeneration has been linked to cognitive decline. 5 key findings →
Participants: 187 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
At baseline, the mean MNA score was 22.5 ± 2.3. 5 key findings →
Participants: 105 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A significant improvement in mental flexibility and planning abilities was observed in both groups (as measured by the Zoo planning test), but no other neuropsychological tests showed improvement. 5 key findings →
Participants: 24 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
At baseline, 219 participants (18%) had CF. The risk for developing CF at 2 years was higher in the control group (risk ratio [RR], 1.88, p = .003). 5 key findings →
Participants: 401 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder with a continuum of stages ranging from preclinical/asymptomatic phase to severe dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A covariate-adjusted linear mixed model for the intention-to-treat sample (N = 353; mean age = 69.7) revealed a significant positive change in dementia literacy at 6 months (standardized change = 0.246; p = 0.012) and a significant improvement in self-efficacy at 12 months (standardized change = 0.157; p = 0.008). 5 key findings →
Design: longitudinal study Participants: 353 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Significant improvement over time was observed in aggregated domain specific composite scores of episodic and semantic memory and spatial abilities. 5 key findings →
Design: longitudinal study Participants: 155 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Within 365 days, 5.2% (N = 10709) of individuals had a delirium or dementia-related hospitalization. 5 key findings →
Participants: 207,343 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This was a retrospective analysis using nationally representative UK general practice population between 1998 and 2018, from electronic health records (Clinical Practice Research Datalink, CPRD, GOLD). 5 key findings →
Participants: 1,219,732 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of 574 older adults, 187 (33%) were admitted. 5 key findings →
Participants: 574 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The study cohort comprised patients with a mean age of 87.2 ± 7.2 years (n = 100), 63% of whom had lived in nursing homes. 4 key findings →
Design: cohort study Participants: 100 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Seriously ill older adults, including those living with Alzheimer’s disease and related dementias (ADRD), often receive disease-focused rehabilitative care in skilled nursing facilities (SNF) with little consideration for their palliative care (PC) needs. 1 key finding →
Design: cross-sectional Participants: 52 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The DEDICATED approach was implemented across 28 wards in three healthcare organizations. 5 key findings →
Design: longitudinal study Participants: 17 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
On average, surveyed caregivers (n = 431) were 78.3 years, had 16 years of education, and were mainly White (88.5%). 5 key findings →
Design: cross-sectional Participants: 431 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Three cohorts of interdisciplinary scholars (N = 53) have started and two have completed DEM-PCCT. 5 key findings →
Design: longitudinal study Participants: 53 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
BackgroundThe progression of cerebral small vessel disease (CSVD) leads to cognitive decline, which can be categorized into subcortical vascular mild cognitive impairment (svMCI) and vascular dementia (VaD).ObjectiveThis research aimed to examine the structural changes in gray (GM) and white matter (WM) in the brain across the disease spectrum. 5 key findings →
Design: longitudinal study Participants: 26 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
MAFLD was associated with an increased risk of WMH over 4.1 years in middle‐aged adults. 5 key findings →
Participants: 2,155 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our results pertaining to menopause-related characteristics, such as age at menopause or menopause hormonal therapy, did not replicate the literature reporting an association with WMH volumes. 5 key findings →
Design: cross-sectional Participants: 9,560 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
49/100
= 0.143). LVI was significantly associated with incident ischemic stroke in the MI cohort (adjusted hazard ratio [HR] 1.82, 95% CI 1.08-3.09), but not in the CCA cohort. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The neurodegenerative disease field has enjoyed extremely limited success in the development of effective therapeutics. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Use of pharmacological treatments is one possible modifiable risk factor for cognitive disorders. 5 key findings →
Design: case-control study Participants: 282,858 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
49/100
Adult-onset neurodegenerative diseases affect millions and negatively impact health care systems worldwide. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This study aimed to examine the associations between nursing home (NH) quality and prevalence of newly admitted NH residents with Alzheimer's disease and related dementias (ADRD), and to assess the extent to which market-level wages for certified nursing assistants (CNAs) and state Medicaid behavioral and mental health add-on policy may influence such associations. 4 key findings →
Design: cohort study Participants: 2,777 Evidence: moderate
Full summary, score breakdown and related studies → Original source
49/100
PA policies varied substantially across private insurers in the US. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This report summarizes the consensus recommendations of a panel of neuropathologists from the United States and Europe to improve the postmortem diagnostic criteria for Alzheimer’s disease. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →